To address shortage, Novo Nordisk will cut production of Victoza to boost supply of Ozempic
Fierce Pharma
NOVEMBER 22, 2023
Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victo | Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza to make more Ozempic.
Let's personalize your content